Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
November 14 2014 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that
Andrew Blight, Chief Scientific Officer, will present at the
Jefferies 2014 Global Healthcare Conference in London on Wednesday,
November 19 at 9:20am GMT.
A live audio webcast of the presentation can be accessed under
“Investor Events” in the Investor section of the Acorda website at
www.acorda.com, or you may use the link:
http://wsw.com/webcast/jeff86/acor
Please log in approximately 5 minutes before the scheduled time
of the presentations to ensure a timely connection. An archived
version of this webcast will be available until December 19, 2014
on the Investors section of www.acorda.com.
About Acorda TherapeuticsFounded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to
improve walking in patients with multiple sclerosis (MS), as
demonstrated by an increase in walking speed.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy. This
pipeline addresses a range of disorders including post-stroke
deficits, Parkinson’s disease, epilepsy, stroke, peripheral nerve
damage, spinal cord injury, neuropathic pain, and heart
failure.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward-Looking StatementsThis press release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially, including our ability to successfully market and sell
Ampyra in the U.S.; third party payers (including governmental
agencies) may not reimburse for the use of Ampyra or our other
products at acceptable rates or at all and may impose restrictive
prior authorization requirements that limit or block prescriptions;
the risk of unfavorable results from future studies of Ampyra or
from our other research and development programs, including
Plumiaz, and CVT-301, or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain
regulatory approval for, or successfully market Plumiaz, CVT-301 or
any other products under development; we may need to raise
additional funds to finance our expanded operations and may not be
able to do so on acceptable terms; the occurrence of adverse safety
events with our products; delays in obtaining or failure to obtain
regulatory approval of or to successfully market Fampyra outside of
the U.S. and our dependence on our collaboration partner Biogen
Idec in connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; failure
to comply with regulatory requirements could result in adverse
action by regulatory agencies; and the ability to obtain additional
financing to support our operations. These and other risks are
described in greater detail in Acorda Therapeutics' filings with
the Securities and Exchange Commission. Acorda may not actually
achieve the goals or plans described in its forward-looking
statements, and investors should not place undue reliance on these
statements. Forward-looking statements made in this release are
made only as of the date hereof, and Acorda disclaims any intent or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this release.
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2024 to May 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From May 2023 to May 2024